Nomura Holdings
EWTX icon

Nomura Holdings’s Edgewise Therapeutics EWTX Stock Holding History

Nomura Holdings’s Portfolio EWTX Stock Details EWTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-10,000
Closed -$248K – 1829
2025
Q4 		$248K Buy
+10,000
New +$201K ﹤0.01% 1720
2024
Q4 		– Sell
-13,335
Closed -$356K – 2245
2024
Q3 		$356K Buy
+13,335
New +$265K ﹤0.01% 1316

Other funds holding EWTX

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Nomura Holdings's EWTX Position: Q1 2026 in Review

Nomura Holdings sold out of Edgewise Therapeutics (EWTX) in Q1 2026, closing a stake of 10,000 shares — an estimated $248K sold.

Nomura Holdings first reported a position in EWTX in Q3 2024 and held it in 2 quarters. The position peaked at $356K in Q3 2024. 214 funds tracked by Wall St. Rank hold EWTX as of Q1 2026.

  • Nomura Holdings reported no remaining Edgewise Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Nomura Holdings sold 10,000 Edgewise Therapeutics shares in Q1 2026, an estimated $248K.
  • Nomura Holdings first reported a position in Edgewise Therapeutics in Q3 2024 and held it in 2 quarters.
  • Nomura Holdings's Edgewise Therapeutics position peaked at $356K in Q3 2024.
  • 214 funds tracked by Wall St. Rank held Edgewise Therapeutics as of Q1 2026.

Based on Nomura Holdings's 13F filing for Q1 2026, filed 15 May 2026.